热门资讯> 正文
Immedica收购Marinus Pharmaceuticals，股价上涨4%
2024-12-30 20:08
- Immedica Pharma AB, a global rare disease company will acquire Marinus Pharmaceuticals (NASDAQ:MRNS) by means of a tender offer and subsequent merger.
- The acquisition complements and further strengthens Immedica’s global rare disease business.
- Immedica, through a wholly owned, direct subsidiary, will initiate a tender offer to acquire all shares of Marinus for a cash purchase price of $0.55 per share, representing a premium of 48% based on Marinus’ closing share price as of December 27.
- The transaction is expected to close in Q1 2025.
- The stock price jumped 4.1% on Monday during re-market hours of trading.
More on Marinus Pharmaceuticals
- Marinus Pharmaceuticals GAAP EPS of -$0.42 in-line, revenue of $8.54M misses by $0.81M
- Marinus downgraded after setback to late-stage trial
- Seeking Alpha’s Quant Rating on Marinus Pharmaceuticals
- Historical earnings data for Marinus Pharmaceuticals
- Financial information for Marinus Pharmaceuticals
推荐文章
一周财经日历 | 超重磅！英伟达、阿里、拼多多财报轮番；美国7月PCE数据来袭
美股机会日报 | 倒计时开始！市场屏息以待鲍威尔讲话；中概股名创优品涨超8%，拼多多涨超4%
一周IPO丨双登股份下周上市，超额认购逾3000倍；佳鑫国际资源火热招股中
AH股追踪丨上证指数一举突破3800点！中芯国际A股飙涨14%，H股涨逾9%
港股异动 | 中兴通讯H股午后持续拉升！盘中涨超13%创历史新高
华盛早报 | 韩国股民疯买港股，外资传大消息，做多中国热情持续攀升；标普“五连阴”！今晚华尔街枕戈以待
美股机会日报 | 关税税率最高15%！美欧敲定框架贸易协议；何小鹏增持310万股，小鹏汽车盘前股价涨超5%
一图看懂 | 哔哩哔哩Q2营收73亿元！上半年手游收入大增68%，经调净利润同比扭亏为盈5.6亿元
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
